Acumen Pharmaceuticals, Inc.
ABOSHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Acumen Pharmaceuticals, Inc. (ABOS) is listed under Biotechnology. At a $228.5M market cap, Acumen Pharmaceuticals, Inc. ranks as a micro-cap company within healthcare. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Market Cap
$228.5M
Beta
0.38
P/E (TTM)
—
P/E (Fwd)
-2.21
EPS (TTM)
$-1.63
EPS (Fwd)
$-1.43
ROE
-120.5%
ROA
-45.8%
Cash
$110.2M
Total Debt
$31.6M
Free CF
-$56.5M
52W Change
135.6%
Annual Financials
Cash vs Debt
Where ABOS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ABOS finished 19.69% above its 150-day moving average ($2.59) and 27.57% above its 200-day moving average ($2.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABOS overbought or oversold?
At the September 3, 2026 close, ABOS's RSI(14) was 69.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Acumen Pharmaceuticals, Inc. holds $110.2M in cash against $31.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$56.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -120.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
ABOS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Acumen Pharmaceuticals, Inc.'s trajectory.